US 12,466,896 B2
Anti-CD3 antibodies and methods of use
Xiaocheng Chen, Foster City, CA (US); Mark S. Dennis, San Carlos, CA (US); Allen J. Ebens, Jr., San Carlos, CA (US); Robert F. Kelley, Petaluma, CA (US); Mary A. Mathieu, San Francisco, CA (US); and Liping L. Sun, South San Francisco, CA (US)
Assigned to Genentech, Inc., South San Francisco, CA (US)
Filed by Genentech, Inc., South San Francisco, CA (US)
Filed on Sep. 6, 2022, as Appl. No. 17/930,018.
Application 17/930,018 is a division of application No. 16/790,656, filed on Feb. 13, 2020, granted, now 11,732,054.
Application 16/790,656 is a division of application No. 15/473,242, filed on Mar. 29, 2017, granted, now 10,640,572, issued on May 5, 2020.
Application 15/473,242 is a division of application No. 14/574,132, filed on Dec. 17, 2014, granted, now 10,174,124, issued on Jan. 8, 2019.
Claims priority of provisional application 62/091,441, filed on Dec. 12, 2014.
Claims priority of provisional application 62/053,582, filed on Sep. 22, 2014.
Claims priority of provisional application 62/026,594, filed on Jul. 18, 2014.
Claims priority of provisional application 61/949,950, filed on Mar. 7, 2014.
Claims priority of provisional application 61/917,346, filed on Dec. 17, 2013.
Prior Publication US 2023/0002506 A1, Jan. 5, 2023
Int. Cl. C07K 16/28 (2006.01); A61K 31/573 (2006.01); A61K 39/395 (2006.01); A61K 45/06 (2006.01); A61K 47/68 (2017.01); C07K 16/30 (2006.01); C07K 16/32 (2006.01); A61K 39/00 (2006.01)
CPC C07K 16/32 (2013.01) [A61K 31/573 (2013.01); A61K 39/39558 (2013.01); A61K 45/06 (2013.01); A61K 47/6881 (2017.08); C07K 16/2809 (2013.01); C07K 16/2827 (2013.01); C07K 16/283 (2013.01); C07K 16/2863 (2013.01); C07K 16/2887 (2013.01); C07K 16/2896 (2013.01); C07K 16/30 (2013.01); A61K 2039/505 (2013.01); C07K 2317/21 (2013.01); C07K 2317/24 (2013.01); C07K 2317/31 (2013.01); C07K 2317/33 (2013.01); C07K 2317/34 (2013.01); C07K 2317/522 (2013.01); C07K 2317/524 (2013.01); C07K 2317/526 (2013.01); C07K 2317/54 (2013.01); C07K 2317/55 (2013.01); C07K 2317/56 (2013.01); C07K 2317/622 (2013.01); C07K 2317/71 (2013.01); C07K 2317/73 (2013.01); C07K 2317/92 (2013.01)] 31 Claims
 
1. A method of producing a bispecific antibody that binds to CD20 and CD3,
the method comprising culturing host cells expressing one or more isolated nucleic acids, the one or more isolated nucleic acids encoding the bispecific antibody, wherein the bispecific antibody comprises:
(a) an anti-CD20 arm comprising a first binding domain, the first binding domain comprising:
a hypervariable region (HVR)-H1 comprising the amino acid sequence of SEQ ID NO: 157,
an HVR-H2 comprising the amino acid sequence of SEQ ID NO: 158,
an HVR-H3 comprising the amino acid sequence of SEQ ID NO: 159,
an HVR-L1 comprising the amino acid sequence of SEQ ID NO: 160,
an HVR-L2 comprising the amino acid sequence of SEQ ID NO: 161, and
an HVR-L3 comprising the amino acid sequence of SEQ ID NO: 162; and
(b) an anti-CD3 arm comprising a second binding domain, the second binding domain comprising:
an HVR-H1 comprising the amino acid sequence of SEQ ID NO: 1,
an HVR-H2 comprising the amino acid sequence of SEQ ID NO: 2,
an HVR-H3 comprising the amino acid sequence of SEQ ID NO: 3,
an HVR-L1 comprising the amino acid sequence of SEQ ID NO: 4,
an HVR-L2 comprising the amino acid sequence of SEQ ID NO: 5, and
an HVR-L3 comprising the amino acid sequence of SEQ ID NO: 6.